Dr Dube and Greg Fenton on ZEN’s potential graphene-based antibiotic, antiviral and antifungal compound

In a recent InvestorIntel interview, Peter Clausi speaks with Dr. Francis Dube, Executive Chairman, and Greg Fenton, CEO and Director of ZEN Graphene Solutions Ltd. (TSXV: ZEN), about ZEN Graphene’s potential graphene-based antibiotic, antiviral and antifungal compound which could be a medical breakthrough in the treatment of numerous human-contracted pathogens including COVID-19.

In this InvestorIntel interview, which may also be viewed on YouTube (click here to subscribe to the InvestorIntel Channel), Greg went on to say, “We unfortunately had to shut down most of our research and development due to COVID-19.” He continued, “Fortunate for us, we had just opened up our own research lab in Guelph. We joined together with our research partners and tested to see if there was anything we could do to help beat this virus.

Dr. Dube told InvestorIntel that ZEN Graphene has already filed patent for a graphene-based virucidal ink to be used in masks, PPE and the HVAC (Heating, ventilation, and air conditioning) sector. He added that the company is now exploring graphene’s use in the fight against the current global pandemic.

On December 22, 2020, ZEN Graphene Solutions announced that it had developed a potential graphene-based antibiotic, antiviral and antifungal compound. Commenting on this news release Greg said, “The versatility of this product is way beyond anything even we could have imagined. Not only the range of pathogens that it is effective against, but how it can be deployed and utilized. It went from us simply talking about bringing our product into coating, to us talking about actually bringing it into the body.”

To watch the full interview, click here

About ZEN Graphene Solutions Ltd.
ZEN is a graphene technology solutions company with a focus on the development of graphene based nanomaterial products and applications. The unique Albany Graphite Project provides the company with a potential competitive advantage in the graphene market as independent labs in Japan, UK, Israel, USA and Canada have independently demonstrated that ZEN’s Albany PureTM Graphite is an ideal precursor material which easily converts (exfoliates) to graphene, using a variety of mechanical, chemical and electrochemical methods. ZEN is focused on commercializing a patent pending graphene-based coating with 99% viricidal activity against

To learn more about ZEN Graphene Solutions Ltd., click here

ZEN Graphene Disclaimer: The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time. The company must receive Health Canada or FDA approvals for any of the products or solutions discussed.

InvestorIntel Disclaimer: ZEN Graphene Solutions Ltd. is an advertorial member of InvestorIntel Corp.

The marvels of graphene technology kick off 2021 with ZEN focused on our health

While we were getting ready for Christmas, on December 22, 2020, ZEN Graphene Solutions Ltd. (TSXV: ZEN) made my head explode.

Well, almost – and there is probably a cure for that (ultimately). But in the meantime, the company’s announcement has rocked ZEN shareholder’s world with a share price increase of just over 50% in a matter of days.

In case you missed it, the press release is here (and watch a great interview with senior management here) as the company reveals the potential blockbusting impact of its graphene science. You might recall that ZEN is working on a virucidal ink for coating masks, but the most recent news is yet another example of the marvels of graphene technology.

Many people know of graphene for its strength (200 times stronger than steel) and ability to conduct heat (10 times more effective than copper) and conduct electricity (1,000 times better than copper), but the world is just coming to understand the biomedical attributes of the diamond that didn’t grow up.

Graphene is a two-dimensional, single layer “crystal” of pure carbon, which is inert. Attaching minute amounts of active “ingredients” to the graphene has resulted in a potential new compound which could be used as an antibiotic, antiviral or antifungal treatment.

That bears repeating, because this is potentially a huge breakthrough.

An alternative that could be used as an antibiotic, antiviral or antifungal treatment.

Recently received testing results from the University Health Network/Mount Sinai Hospital Department of Microbiology in Toronto indicate that this patent pending formulation could be a medical breakthrough in the treatment of numerous human-contracted pathogens.

The company commenced cytotoxicity (toxicity to cells) studies in lab animals in October 2020, with results expected in January 2021. Pending the outcome of the testing to demonstrate the safety of the graphene compound, upon successful completion the company will then seek to move immediately to human trials in 2021 with one or more pharma partners.

Immediate and obvious uses for a successful graphene compound product would be the potential use to treat infection of upper and lower respiratory tract – where COVID-19 is a major contributor – via a dry-powder inhaler or a nasal spray to maximize local concentrations directly at the site of infection. Other immediate obvious uses are the potential role in ear, eye, and fungal infections treatments.

If the graphene compound is shown to be safe and effective in human trials, subject to regulatory approvals, it would also provide a viable alternative to many of the antibiotic-resistant super-bugs.

Think about that – we all know someone who has had an issue with this and it is becoming unfortunately more common in hospital care.

The potential impact of this discovery and breakthrough should not be underestimated. The world has thus-far mostly focussed on the mechanical and physical aspects of using graphene as an enhancer. A new potential medical treatment? Antibiotic, antiviral or antifungal all in one?

Boom – just made my head explode….again!